Interleukin-22 Treatment
Interleukin-22 Treatment - Related Videos
03:33
Evaluating the Effects of Fecal Microbiota Transplantation in an Interleukin-10 Deficient Mouse
0 Views •
2025
This video demonstrates a procedure of fecal microbiota transplantation in an interleukin-10 deficient mouse with colon inflammation. Colonized fecal microbes in the gut release secondary metabolites, eliciting anti-inflammatory cytokine release and reducing colon inflammation.
10:30
Visualization of IL-22-expressing Lymphocytes Using Reporter Mice
0 Views •
Cited by 2 •
2017
We describe here a transgenic reporter mouse model to visualize the IL-22-producing cells inside different mouse tissues. This method can be used to track the location of other cytokines or secretary proteins in the mouse.
08:43
Microinjection of Interleukin-6 into the Bloodstream of TSC Zebrafish Larvae to Study Neuropsychiatric Disorder-Like Behaviors
0 Views •
2026
To model how inflammatory signals influence neurodevelopment in genetically susceptible organisms, we present a protocol for microinjecting IL-6 into the duct of Cuvier (common cardinal vein) of zebrafish larvae, enabling controlled induction of inflammation and assessment of its developmental impact in the context of tuberous sclerosis complex (TSC).
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
0 Views •
Cited by 26 •
2013
Psoriasis is a chronic, immune-mediated inflammatory skin disease. The Goeckerman regimen, formulated for the treatment of psoriasis, consists of exposure to ultraviolet B (UVB) light and application of crude coal tar (CCT). The following protocol is for the administration of Goeckerman therapy for the treatment of moderate-to-severe psoriasis.
10:22
MRM Microcoil Performance Calibration and Usage Demonstrated on Medicago truncatula Roots at 22 T
0 Views •
Cited by 3 •
2021
A protocol to study biological tissue at high spatial resolution using ultra-high field magnetic resonance microscopy (MRM) using microcoils is presented. Step-by-step instructions are provided for characterizing the microcoils. Finally, optimization of imaging is demonstrated on plant roots.
FAQs
After IL-22 engages its receptor on epithelial cells, it activates signaling pathways such as JAK-STAT3. This signaling can increase antimicrobial peptide production, support epithelial-cell survival, and promote tissue repair. The combination links barrier restoration with local defense, making receptor-driven epithelial responses central when investigators assess whether treatment improves protection during infection or recovery after tissue injury.
IL-22 acts mainly on non-immune cells rather than directly reshaping immune-cell behavior. That distinction matters because treatment can strengthen the tissue barrier and its antimicrobial environment without being interpreted simply as a conventional immune-cell activating therapy. In infection studies, researchers therefore examine epithelial outcomes alongside inflammatory changes to determine how host protection is being achieved.
Treatment outcomes depend strongly on timing, dose, and the surrounding inflammatory context. A carefully positioned intervention may support barrier repair or host defense, whereas excessive or persistent signaling can contribute to tissue pathology. These variables prevent a universal interpretation of benefit: the same cytokine-based approach must be evaluated according to whether tissue is infected, injured, or already experiencing substantial inflammation.
Studies can compare treatment across the intestine, lungs, and skin, where barrier protection is especially relevant. Investigators can then ask whether IL-22-associated responses support antimicrobial defense, epithelial survival, or tissue repair in each setting. Comparing these outcomes helps reveal how tissue location and inflammatory context shape therapeutic value.
Researchers study this approach when infection or tissue injury threatens epithelial barrier function, particularly in the intestine, lungs, or skin. The research goal is to determine whether reinforcing epithelial survival, repair, and antimicrobial peptide production improves host defense. These applications place IL-22 treatment at the intersection of barrier biology, infection, and tissue recovery.
An improved outcome should not be judged solely by evidence of stronger signaling. Useful interpretation considers whether epithelial repair and antimicrobial responses occur without accompanying tissue pathology. Because persistent or excessive IL-22 activity may be harmful, infection and immunology studies must weigh protective barrier effects against the inflammatory context and duration of treatment.